ARS Pharmaceuticals, Inc. (SPRY)Healthcare | Biotechnology | San Diego, United States | NasdaqGM
8.12 USD
-0.07
(-0.795%) ⇩
(April 17, 2026, 11:41 a.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:50 p.m. EDT
SPRY is currently trading near its 52-week low, with a negative earnings outlook and high overall risk. The recent news highlights some positive developments, such as increased sales and potential global expansion, but the stock remains heavily shorted and has a weak financial position. While there are some bullish signals in the options market, the overall fundamentals and recent price action suggest caution. It may be a buy-the-dip opportunity for short-term traders, but long-term investors should wait for more positive signs before committing. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.180255 |
| AutoETS | 0.207425 |
| AutoARIMA | 0.207429 |
| AutoTheta | 0.220757 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 15.11 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.573 |
| Excess Kurtosis | -0.73 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 147.486 |
| Revenue per Share | 0.855 |
| Market Cap | 805,797,568 |
| Forward P/E | -10.71 |
| Beta | 0.93 |
| Profit Margins | -203.25% |
| Website | https://ars-pharma.com |
As of April 11, 2026, 3:50 p.m. EDT: The options activity indicates mixed signals. Call options are showing some interest in higher prices, particularly for strikes above the current price, with elevated IV and OI for out-of-the-money strikes. However, the puts also show significant activity, especially for strikes below the current price, indicating potential bearish sentiment. The overall options data suggests uncertainty about the near-term direction, with a balance between bullish and bearish speculation.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.42877096 |
| Address1 | 11,682 El Camino Real |
| Address2 | Suite 300 |
| All Time High | 63.41 |
| All Time Low | 2.55 |
| Ask | 10.35 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,278,600 |
| Average Daily Volume3 Month | 1,343,298 |
| Average Volume | 1,343,298 |
| Average Volume10Days | 1,278,600 |
| Beta | 0.925 |
| Bid | 5.97 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 1.151 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.115 |
| Current Ratio | 7.278 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 8.35 |
| Day Low | 8.05 |
| Debt To Equity | 147.486 |
| Display Name | ARS Pharmaceuticals |
| Earnings Call Timestamp End | 1,773,059,400 |
| Earnings Call Timestamp Start | 1,773,059,400 |
| Earnings Timestamp | 1,773,059,400 |
| Earnings Timestamp End | 1,778,761,800 |
| Earnings Timestamp Start | 1,778,761,800 |
| Ebitda | -178,080,992 |
| Ebitda Margins | -2.11302 |
| Enterprise To Ebitda | -4.132 |
| Enterprise To Revenue | 8.73 |
| Enterprise Value | 735,779,968 |
| Eps Current Year | -1.5675 |
| Eps Forward | -0.7575 |
| Eps Trailing Twelve Months | -1.74 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.7213 |
| Fifty Day Average Change | -0.60630035 |
| Fifty Day Average Change Percent | -0.06951949 |
| Fifty Two Week Change Percent | -42.877094 |
| Fifty Two Week High | 18.9 |
| Fifty Two Week High Change | -10.785 |
| Fifty Two Week High Change Percent | -0.5706349 |
| Fifty Two Week Low | 6.66 |
| Fifty Two Week Low Change | 1.4549999 |
| Fifty Two Week Low Change Percent | 0.21846846 |
| Fifty Two Week Range | 6.66 - 18.9 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,607,092,200,000 |
| Float Shares | 41,035,605 |
| Forward Eps | -0.7575 |
| Forward P E | -10.712872 |
| Free Cashflow | -94,588,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 158 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.60126996 |
| Gross Profits | 50,674,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.16747999 |
| Held Percent Institutions | 0.93595004 |
| Implied Shares Outstanding | 99,297,307 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. |
| Long Name | ARS Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 805,797,568 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_585213447 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -171,298,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 813,244,944 |
| Number Of Analyst Opinions | 7 |
| Open | 8.35 |
| Operating Cashflow | -170,866,000 |
| Operating Margins | -1.47631 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 858 771 9307 |
| Previous Close | 8.18 |
| Price Eps Current Year | -5.1770334 |
| Price Hint | 2 |
| Price To Book | 7.0503907 |
| Price To Sales Trailing12 Months | 9.561185 |
| Profit Margins | -2.03254 |
| Quick Ratio | 6.931 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.065000534 |
| Regular Market Change Percent | -0.79462755 |
| Regular Market Day High | 8.35 |
| Regular Market Day Low | 8.05 |
| Regular Market Day Range | 8.05 - 8.35 |
| Regular Market Open | 8.35 |
| Regular Market Previous Close | 8.18 |
| Regular Market Price | 8.115 |
| Regular Market Time | 1,776,440,477 |
| Regular Market Volume | 339,425 |
| Return On Assets | -0.33044997 |
| Return On Equity | -0.9233 |
| Revenue Growth | -0.676 |
| Revenue Per Share | 0.855 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 99,297,307 |
| Shares Percent Shares Out | 0.2552 |
| Shares Short | 25,341,296 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 22,750,867 |
| Short Name | ARS Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.41459998 |
| Short Ratio | 15.69 |
| Source Interval | 15 |
| State | CA |
| Symbol | SPRY |
| Target High Price | 34.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 26.71429 |
| Target Median Price | 26.0 |
| Total Cash | 244,986,000 |
| Total Cash Per Share | 2.467 |
| Total Debt | 168,514,000 |
| Total Revenue | 84,278,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.74 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 11.0765 |
| Two Hundred Day Average Change | -2.9615002 |
| Two Hundred Day Average Change Percent | -0.26736787 |
| Type Disp | Equity |
| Volume | 339,425 |
| Website | https://ars-pharma.com |
| Zip | 92,130 |